Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

N/ACompletedNCT04609930

University Hospital, Montpellier143 enrolled

Overview

The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.

Study Type

OBSERVATIONAL

Enrollment

143

Conditions

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

Interventions

Anti-PD-1 or anti-PD-L1DRUG

Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Electronic patient file "DxCare" at the University Hospitals of Montpellier * Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy according to central pharmacy records Exclusion Criteria: * No mention of % eosinophilia in the patient file

Locations (1)

UH Montpellier

Montpellier, France

Outcomes

Primary Outcomes

Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1

Time frame: Before treatment (before day 0) versus after (15 days)

Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1

Time frame: Before treatment (before day 0) versus after (1 month)

Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1

Time frame: Before treatment (before day 0) versus after (3 months)

Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1

Time frame: Before treatment (before day 0) versus after (6 months)

Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1

Time frame: Before treatment (before day 0) versus after (12 months)

Secondary Outcomes

Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies

Name of pathology

Time frame: Day 0

Age (years)

Time frame: Day 0

Sex (male/female)

Time frame: Day 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT04609930 - Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation | Crick | Crick